


Memorial Sloan Kettering Cancer Center
is pleased to announce

CLINICAL APPLICATION OF CAR T CELLS

MARCH 10-11, 2016



Conference Location:

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street, New York, NY 10065




Memorial Sloan Kettering
Cancer Center™

Featuring national and international experts including world renowned Keynote Speakers, and a cocktail reception and dinner at The Museum of the City of New York on Thursday, March 10, 2016.

Keynote Speakers



Zelig Eshhar, PhD
Professor of Immunology
The Weizmann Institute of Science,
Israel




Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Memorial Sloan Kettering
Cancer Center

Cocktail Reception & Dinner

Please join us on the evening of Thursday, March 10th for a cocktail reception, dinner, and tour at **THE MUSEUM OF THE CITY OF NEW YORK.**

**RSVP details will be sent with registration confirmation.*



Course Overview

Chimeric antigen receptor (CAR) T-cell (“Living Drug”) immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more are on track to be initiated next year.

Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside – choosing the ideal antigen target, constructing clinical grade CARs and vectors, investigating CARs in clinically relevant models, manufacturing, quality control, developing protocols for FDA approval, optimizing consent forms that cover emerging ethical issues, managing complications, and conducting world-class correlative science.

In addition to the MSK faculty, national and international experts will discuss clinical and translational aspects of CARs, both for hematological malignancies and solid tumors.

TARGET AUDIENCE

The target audience is medical oncologists and oncology fellows in training, basic scientists and research fellows in training, immunologists, and surgeons with interest in tumor immunology and immunotherapy.

PRESENTATIONS & PANEL DISCUSSION TOPICS

- CAR mechanics
- CD19-targeted CARs: Clinical trials and beyond
- CARs to target Non-Hodgkin Lymphoma
- State of the art clinical-grade CAR T-cell manufacturing and production
- Beyond regulatory approvals: NIH RAC, IRB, IND, and FDA
- Driving CARs through solid tumors
- Safety belts for CARs
- Next-generation CARs

For more information, or to register, visit:

WWW.MSKCC.ORG/CARTcell



Course Faculty

MSK COURSE DIRECTOR



Prasad S. Adusumilli, MD, FACS, FCCP
Member, Center for Cell Engineering
& Center for Cellular Therapeutics
Deputy Chief, Thoracic Surgery Service

MSK COURSE CO-DIRECTORS



Renier J. Brentjens, MD, PhD
Director, Center for
Cellular Therapeutics



Michel Sadelain, MD, PhD
Director, Center for
Cell Engineering

MSK FACULTY

Kevin J. Curran, MD
Pediatrics

Sergio A. Giral, MD
Chief, Bone Marrow Transplant

Roisin E. O’Cearbhaill, MD
Gynecologic Medicine

Jae Park, MD
Leukemia

Isabelle Riviere, PhD
Cell Therapy & Cell Engineering

Paul Sabbatini, MD
Deputy Physician-in-Chief

Craig S. Sauter, MD
Bone Marrow Transplant

David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program

Marcel R.M. van den Brink, MD, PhD
Division Head, Hematologic
Oncology – Medicine

Roger S. Wilson, MD
Institutional Review Board

Jedd D. Wolchok, MD, PhD
Chief, Melanoma & Immunotherapeutics

INVITED FACULTY

Steven M. Albelda, MD
University of Pennsylvania

Christine Brown, PhD
City of Hope

Laurence J. N. Cooper, MD, PhD
MD Anderson

Marco L. Davila, MD, PhD
Moffitt Cancer Center

Soldano Ferrone, MD, PhD
Massachusetts General Hospital

Noelle Frey, MD, MSCE
University of Pennsylvania

Rebecca A. Gardner, MD
Seattle Children’s Hospital

Adrian P. Gee, PhD
Baylor Medical Center

David Gilham, PhD
University of Manchester

Stephen Gottschalk, MD
Baylor Medical Center

Michael C. V. Jensen, MD
Seattle Children’s Hospital

James N. Kochenderfer, MD
National Cancer Institute

Daniel W. Lee, MD
National Cancer Institute

Bruce L. Levine, PhD
University of Pennsylvania

John Maher, PhD, FRCPath
King’s College London

Shannon L. Maude, MD, PhD
Children’s Hospital of Philadelphia

Marcela V. Maus, MD, PhD
Massachusetts General Hospital

David L. Porter, MD
University of Pennsylvania

Stephen J. Schuster, MD
University of Pennsylvania

Cameron J. Turtle, MD, PhD
Fred Hutchinson Cancer Center

Scientific Agenda

THURSDAY, MARCH 10

8:00-8:45	BREAKFAST & REGISTRATION	
8:45-8:50	WELCOME	
8:50-9:00	INAUGURAL ADDRESS	
	NEW DIRECTIONS IN T-CELL ENGINEERING	
	MODERATORS Michel Sadelain, MD, PhD Marcel R.M. van den Brink, MD, PhD	
9:00-9:20	Challenges in CAR Targeting – New Approaches to Target the ErbB Family	John Maher, PhD, FRCPATH
9:20-9:40	Crafting CAR T-cell Products of Defined Cellular Composition	Michael C. V. Jensen, MD
9:40-10:00	Engineering CARs and Cytokines for Therapeutic Applications	Laurence J. N. Cooper, MD, PhD
10:00-10:15	DISCUSSION	
10:15-10:30	COFFEE BREAK	
	CARS FOR HEMATOLOGICAL MALIGNANCIES – PART I	
	MODERATORS Jae Park, MD David L. Porter, MD	
10:30-10:45	Clinical Trials for B-cell ALL: MSK Experience	Jae Park, MD
10:45-11:00	Clinical Trials for B-cell ALL: NCI Experience	Daniel W. Lee, MD
11:00-11:15	Clinical Trials for B-cell ALL: Seattle Children’s Experience	Rebecca A. Gardner, MD
11:15-11:30	DISCUSSION	
11:30-12:00	KEYNOTE ADDRESS	Zelig Eshhar, PhD
12:00-1:00	LUNCH	
	PANEL DISCUSSION	
	MODERATORS Prasad S. Adusumilli, MD, FACS, FCCP Stephen Gottschalk, MD	
1:00-2:00	Driving CARs Through Regulatory Approvals & Building a CAR T-Cell Program	Sergio A. Giralto, MD Paul Sabbatini, MD Roger S. Wilson, MD
	CARS FOR HEMATOLOGICAL MALIGNANCIES – PART II	
	MODERATORS John Maher, PhD, FRCPATH Renier J. Brentjens, MD, PhD	
2:00-2:15	CARs for NHL and Myeloma at NCI	James N. Kochenderfer, MD
2:15-2:30	CARs for CLL at UPenn	David L. Porter, MD
2:30-2:45	Immunotherapy for NHL with CD19 CAR T cells of Defined Composition	Cameron J. Turtle, MD, PhD
2:45-3:00	DISCUSSION	
3:00-3:15	COFFEE	
	SAFETY BELTS FOR CARS	
	MODERATORS Kevin J. Curran, MD Soldano Ferrone, MD, PhD Marco L. Davila, MD, PhD	
3:15-3:30	CAR T-cell Toxicity Management Algorithms: MSK Approach	Kevin J. Curran, MD
3:30-3:45	Defining Cytokine Release Syndrome	Noelle Frey, MD, MSCE
3:45-4:00	Managing Cytokine Release Syndrome	Daniel W. Lee, MD
4:00-4:15	Potential Toxicities of CAR T cells – Beyond Cytokine Release Syndrome	Marcela V. Maus, MD, PhD
4:15-4:30	Predicting and Preventing CAR T-cell Toxicity	Marco L. Davila, MD, PhD
	POSTER PRESENTATIONS	
	MODERATORS Kevin J. Curran, MD Roisin E. O’Cearbhaill, MD Christine Brown, PhD	
4:30-5:30	Poster Presentations (serving wine and cheese)	
6:00-9:00	Cocktail Reception, Museum Tour, and Dinner at THE MUSEUM OF THE CITY OF NEW YORK 1220 5th Avenue, New York <i>Confirmations are required. RSVP details will be sent upon registration.</i>	

FRIDAY, MARCH 11

8:00-8:45	BREAKFAST	
9:00-9:15	INTRODUCTORY REMARKS	
	CARS FOR SOLID TUMORS	
	MODERATORS Prasad S. Adusumilli, MD, FACS, FCCP Steven M. Albelda, MD	
9:15-9:30	Augmenting CAR T-cell Function in Solid Tumors	Steven M. Albelda, MD
9:30-9:45	Mesothelin Targeted CARs for Lung, Breast Cancers, and Mesothelioma	Prasad S. Adusumilli, MD, FACS, FCCP
9:45-10:00	HER-2 Targeted CARs for Sarcoma	Stephen Gottschalk, MD
10:00-10:15	CSPG-4 Targeted CARs for Solid Tumors	Soldano Ferrone, MD, PhD
10:15-10:30	IL13R α 2 Targeted CARs for Glioma	Christine Brown, PhD
10:30-10:45	DISCUSSION	
10:45-11:00	COFFEE BREAK	
11:00-11:15	Immune Response Monitoring in Solid Tumor Therapies	Jedd D. Wolchok, MD, PhD
	CARS FOR HEMATOLOGICAL MALIGNANCIES – PART III	
	MODERATORS Craig S. Sauter, MD Cameron J. Turtle, MD, PhD	
11:15-11:30	Phase II CAR T-cell Therapy Trials for NHL at UPenn	Stephen J. Schuster, MD
11:30-11:45	CARs Post Autologous Transplant for NHL at MSK	Craig S. Sauter, MD
11:45-12:00	Clinical Trials for B-cell ALL: UPenn/CHOP Pediatric Experience	Shannon L. Maude, MD, PhD
12:00-1:00	LUNCH	
1:00-1:30	KEYNOTE ADDRESS	Michel Sadelain, MD, PhD
	CAR T-CELL MANUFACTURING	
	MODERATORS Isabelle Riviere, PhD Adrian P. Gee, PhD Bruce L. Levine, PhD	
1:30-1:50	Evolution of CAR Manufacturing at MSK	Isabelle Riviere, PhD
1:50-2:10	Chemistry, Manufacturing, and Controls (CMC) for CARs	Adrian P. Gee, PhD
2:10-2:30	Evolution and Globalization of CAR T-Cell Therapies	Bruce L. Levine, PhD
2:30-2:45	DISCUSSION	
2:45-3:10	Bench to Bedside to Biotech	Renier J. Brentjens, MD, PhD
3:10-3:30	COFFEE	
	NEXT GENERATION CARS	
	MODERATORS David A. Scheinberg, MD, PhD David Gilham, PhD	
3:30-3:50	Preclinical Development of CAR T cells	David Gilham, PhD
3:50-4:10	IL-12 Secreting CARs	Roisin E. O’Cearbhaill, MD
4:10-4:30	Overcoming Antigen Escape by Multiplexing of CAR T-cell Targets	Michael C. V. Jensen, MD
4:30-4:50	Potentiating CARs with Checkpoint Blockade	Prasad S. Adusumilli, MD, FACS, FCCP
4:50-5:00	CONCLUDING REMARKS	

Registration

EARLY*

GENERAL

\$200

\$250

Physicians (MDs, PhDs, DOs)

\$75

\$100

Residents, Fellows

*Deadline for early registration is February 15, 2016.

To register, please go to:

WWW.MSKCC.ORG/CARTcell

Registration includes an electronic syllabus and other related handout materials, continental breakfast, lunch, and refreshment breaks. Special meals are available upon request, including vegetarian, kosher, or gluten-free. Please let us know if we can assist you with any special dietary needs.

ACCOMMODATIONS

For information on hotels in the area of MSK with discounted rates, please visit: www.mskcc.org/accommodations

CONTACT

Office of Continuing Medical Education
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th Floor
New York, New York 10017
(646) 227-2025
cme@mskcc.org

 /MSKCME

 @MSKCME

ACCREDITATION STATEMENT

Memorial Sloan Kettering Cancer Center (MSKCC) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. MSKCC designates this conference for a maximum of **12.75 AMA PRA Category 1 Credits™**. Each physician should claim only those hours of credit he/she actually spent in the conference.

EVALUATION

A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

OUTCOMES MEASUREMENT SURVEY

Six months after the end of the course, an Outcomes Measurement survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

FACULTY DISCLOSURE

It is the policy of MSKCC to make every effort to ensure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSKCC are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSKCC requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.